Roberto Pili, MD, professor of oncology, chief, genitourinary section leader, Genitourinary Program, Department of Medicine, Roswell Park Cancer Center, discusses the efficacy of tasquinimod in men with metastatic castration-resistant prostate cancer
Roberto Pili, MD, professor of oncology, chief, genitourinary section leader, Genitourinary Program, Department of Medicine, Roswell Park Cancer Center, discusses the efficacy of tasquinimod in men with metastatic castration-resistant prostate cancer (CRPC).
Clinical Pearls:
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More